What Is a GI-MAP Test, and What Does It Actually Measure?
By Tara6 min read
A GI-MAP test is a stool panel that uses DNA sequencing to measure what is living in your digestive tract and how that tract is behaving. It is one of the most common tests ordered in functional health, and also one of the most misunderstood, partly because the report runs to a dozen pages of unfamiliar organism names, and partly because a lot of what is written about it online is either marketing or alarmism. This is a plain walk through what the panel measures, section by section, and what a result can and cannot tell you. We order this test often, so we also want to be direct about its limits.
How the test works
GI-MAP stands for Gastrointestinal Microbial Assay Plus. It is run by Diagnostic Solutions Laboratory on a single stool sample you collect at home and mail back.
The method matters. Older stool testing relied on culturing: taking the sample, trying to grow organisms from it in a dish, and reporting what grew. The problem is that most gut organisms are anaerobic, meaning they die on contact with oxygen, so a great deal of what was actually in the sample never grew and never got reported.
GI-MAP instead uses quantitative polymerase chain reaction, or qPCR. It looks for specific stretches of DNA belonging to specific organisms, and counts how many copies are present. A dead organism still has DNA, so the result does not depend on keeping anything alive in transit. It also produces a number rather than a presence-or-absence, which is what makes results comparable when you retest later.
The trade-off is that qPCR only finds what it is designed to look for. The panel targets a defined list of organisms. Something not on that list will not appear, no matter how much of it is present. This is worth understanding, because a clear report does not mean nothing is there; it means nothing the panel searches for is there in quantity.
Pathogens: the section that gets read first
The report opens with frank pathogens: the organisms associated with acute illness. Bacterial targets include Campylobacter, C. difficile toxins A and B, certain E. coli strains, Salmonella, Shigella, Vibrio and Yersinia. There are parasitic targets including Cryptosporidium, Entamoeba histolytica and Giardia, and viral targets including norovirus and adenovirus.
Most people run a clean pathogen section, and that is the expected result. Where something does appear, the number matters as much as the finding. DNA methods are sensitive enough to detect an organism at levels that are not necessarily driving symptoms, and detection is not the same thing as infection.
This is the part of the report where a functional test stops and clinical care starts. A positive C. difficile toxin result, for instance, belongs with a physician, not a supplement protocol.
H. pylori and its virulence factors
Helicobacter pylori gets its own section, and this is one of the more genuinely useful parts of the panel.
H. pylori is common: a substantial share of the world's population carries it, and many carry it without symptoms for life. What GI-MAP adds is a set of virulence factor genes alongside the organism itself: markers such as cagA, vacA, babA and others. These genes are associated with the strains more often linked to ulceration and to more significant inflammation of the stomach lining.
The practical value is that it separates carrying H. pylori from carrying a strain with a more aggressive genetic profile. That distinction changes the conversation, and it is not one a standard breath or antigen test can give you.
As above: H. pylori with virulence factors and upper GI symptoms is a reason to see a physician, and we say so.
Commensal and opportunistic bacteria
The middle of the report covers the organisms that are supposed to be there, and the ones that are ordinarily present in small numbers but can overgrow.
Commensal or normal flora (the Bacteroides, Bifidobacterium, Lactobacillus and Faecalibacterium groups among others) are reported against a reference range. Low diversity or several groups reading low is a more meaningful pattern than any single low value.
Opportunistic organisms are grouped separately. These are not pathogens. They are ordinary residents that become a problem mainly when the ecosystem around them shifts: after antibiotics, during a long stretch of low stomach acid, or when the commensal groups that would otherwise crowd them out are depleted. Streptococcus, Staphylococcus, Klebsiella, Pseudomonas, Enterococcus and various Proteobacteria appear here.
The interpretive skill is in reading these two sections against each other. A moderate opportunistic overgrowth on a background of healthy commensals is a very different picture from the same number on a background of depleted flora, and it points somewhere different.
Fungi and yeast
Candida species, Geotrichum, Microsporidium and Rodotorula are measured here.
This section is worth reading with some caution, in both directions. Yeast is a normal resident of the gut, and detection on its own is not a finding. At the same time, yeast is unevenly distributed through stool, so a single sample can read low while a genuine overgrowth is present.
In other words: a high result is informative, a low result is weaker evidence than it looks, and neither should be read in isolation from symptoms.
Intestinal health markers: often the most useful page
The last section of a GI-MAP test measures how the gut is functioning rather than what is living in it, and in our experience it is frequently the page that changes what happens next.
Steatocrit estimates fat in the stool, which speaks to fat digestion and absorption. Pancreatic elastase-1 is a marker of pancreatic enzyme output. Beta-glucuronidase relates to how compounds the liver has packaged for excretion are handled in the gut, which is why it comes up in conversations about hormone clearance.
Secretory IgA is the antibody the gut lining secretes as a first line of defence; both high and low results carry meaning. Anti-gliadin IgA reflects a mucosal immune response to gluten specifically. Occult blood flags blood not visible in the sample.
Calprotectin is the marker to understand properly. It is a neutrophil protein that rises with intestinal inflammation, and it is used in conventional gastroenterology to help distinguish inflammatory bowel disease from irritable bowel syndrome. A meaningfully elevated calprotectin is not something to work on nutritionally while hoping it settles; it is a reason to be seen by a gastroenterologist.
Zonulin, offered as an add-on, is a protein involved in the regulation of the junctions between intestinal cells. It is the marker most often pointed to in discussions of intestinal permeability, and it is also the one with the most active scientific debate around what stool zonulin assays are truly measuring.
What a GI-MAP test cannot tell you
We would rather set expectations honestly, because a test oversold is a test that disappoints.
It does not diagnose disease. It is a lab-developed test, interpreted against the laboratory's own reference ranges, and it is not a substitute for diagnostic workup where that is warranted.
It is a snapshot of one sample on one day, from a system that varies with what you ate that week, whether you have recently taken antibiotics or antifungals, and where in the transit the sample came from.
It does not reliably assess the small intestine. Stool reflects the colon. Suspected small intestinal bacterial overgrowth is a breath test question, not a stool test question.
And it does not, on its own, produce a plan. A report is a set of numbers. What makes it useful is reading those numbers against your history, your symptoms and the rest of your labs, which is the part that takes a practitioner.
Questions worth asking before you order one
Ask what is included, because the panel has add-ons and zonulin is usually one of them.
Ask who is interpreting it and what that costs. The test fee and the interpretation are often separate, and a report handed over without a conversation is of limited use.
Ask what would change based on the result. If the answer is the same protocol regardless of what comes back, the test is not earning its cost.
Ask about retesting. Knowing whether a follow-up is expected, and roughly when, tells you the real cost of the path you are starting.
And ask what happens if something clinical turns up: a positive pathogen, an elevated calprotectin, a positive occult blood. You want to hear a clear answer about referral.
Common questions
- Is a GI-MAP test covered by insurance?
- Usually not. GI-MAP is a lab-developed test ordered outside conventional diagnostic pathways, so it is typically paid out of pocket. Some people are able to use an HSA or FSA. Because coverage and pricing vary by how the test is ordered, ask for the full cost (test plus interpretation) in writing before you commit.
- How long do GI-MAP results take?
- Turnaround is commonly one to two weeks from the point the laboratory receives your sample, though it varies. The bigger variable is usually how quickly the sample gets mailed back after it arrives, since collection happens on your schedule.
- Do I need to stop supplements before a GI-MAP test?
- Guidance varies and it matters more than people expect. Probiotics, antibiotics, antifungals and antiparasitics can all shift what the panel finds. Follow the collection instructions that come with your kit, and tell whoever is interpreting the result exactly what you were taking, because it changes how the numbers should be read.
- Is the GI-MAP test worth it?
- It is worth it when the result would change what you do next, and when someone is going to interpret it against your history rather than hand you a PDF. It is poor value as a general curiosity, as a first step when clear red-flag symptoms need a physician, or when the same protocol was going to be recommended regardless of the findings.